Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2021 pubmed 17 citations

Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis.

Acen. Ester Lilian EL; Biraro. Irene Andia IA; Worodria. William W; Joloba. Moses L ML; Nkeeto. Bill B; Musaazi. Joseph J; Kateete. David Patrick DP

Key Findings

  • Active pulmonary TB patients have significantly lower serum vitamin D compared to healthy controls.
  • Circulating LL‑37 levels are higher in TB patients, but local lung expression of LL‑37 is reduced.
  • A strong statistical link (p < 0.001) exists between vitamin D deficiency and altered LL‑37 levels in TB.

Practical Outcomes

  • For biohackers focused on immunity, maintaining adequate vitamin D status (e.g., 2000–4000 IU daily, depending on baseline levels) may support antimicrobial defenses. While LL‑37 itself isn’t directly supplementable, ensuring sufficient vitamin D could help modulate its activity. However, the findings are specific to TB patients and don’t translate into a universal performance boost for healthy individuals.

Summary

People with active lung TB tend to have low vitamin D levels and higher amounts of the immune peptide LL‑37 in their blood, while the local lung tissue shows less LL‑37. This pattern suggests that low vitamin D may weaken the body's defense against TB, and that boosting vitamin D could help protect against the disease.

Abstract

Tuberculosis remains a global threat and a public health problem that has eluded attempts to eradicate it. Low vitamin D levels have been identified as a risk factor for tuberculosis infection and disease. The human cathelicidin LL-37 has both antimicrobial and immunomodulatory properties and is dependent on vitamin D status. This systematic review attempts to compare vitamin D andLL-37 levels among adult pulmonary tuberculosis patients to non-pulmonary TB individuals between 16-75 years globally and to determine the association between vitamin D and cathelicidin and any contributing factor among the two study groups. We performed a search, through PubMed, HINARI, Google Scholar, EBSCOhost, and databases. A narrative synthesis through evaluation of vitamin D and LL-37 levels, the association of vitamin D and LL-37, and other variables in individual primary studies were performed. A random-effect model was performed and weighted means were pooled at a 95% confidence interval. This protocol is registered under the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42019127232. Of the 2507 articles selected12 studies were eligible for the systematic review and of these only nine were included in the meta-analysis for vitamin D levels and six for LL-37 levels. Eight studies were performed in Asia, three in Europe, and only one study in Africa. The mean age of the participants was 37.3&#xb1;9.9 yrs. We found low vitamin D and high cathelicidin levels among the tuberculosis patients compared to non-tuberculosis individuals to non-tuberculosis. A significant difference was observed in both vitamin D and LL-37 levels among tuberculosis patients and non-tuberculosis individuals (p = &lt; 0.001). This study demonstrated that active pulmonary tuberculosis disease is associated with hypovitaminosis D and elevated circulatory cathelicidin levels with low local LL-37 expression. This confirms that vitamin D status has a protective role against tuberculosis disease.

Study Information

Provider

pubmed

Year

2021

Date

2021-06-11T00:00:00.000Z

DOI

10.1371/journal.pone.0252762

Citations

17

References

66